Keyphrases
Antibody Activity
100%
COVID-19
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Reduced Antibodies
100%
Delta Virus
100%
Neutralizing Antibodies
66%
Chronic Inflammatory Diseases
66%
TNF Inhibitors
66%
Virus
33%
Monotherapy
33%
Immunosuppressive Therapy
33%
Monoclonal Antibody
33%
Healthy Individuals
33%
Vaccination
33%
Antibody Response
33%
Immunization
33%
Immunogenic
33%
Longitudinal Analysis
33%
Immunosuppressive Drugs
33%
NIAID
33%
Susceptible Population
33%
Influenza
33%
Center of Excellence
33%
Fc Effector Function
33%
Influenza Vaccine
33%
Antibody-mediated Protection
33%
Neutralizing Titer
33%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
33%
Capacity Function
33%
BNT162b2 Vaccine
33%
Innovation Centers
33%
Third mRNA Vaccine Dose
33%
Serum Neutralizing Antibodies
33%
Antibody Effector Function
33%
Vaccine Innovation
33%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor Inhibitor
100%
SARS Coronavirus
100%
Hepatitis Delta Virus
100%
Messenger RNA
100%
Neutralizing Antibody
50%
Inflammatory Disease
50%
mRNA Vaccine
50%
Infection
25%
Monotherapy
25%
Immunosuppressive Agent
25%
Monoclonal Antibody
25%
Live Attenuated Influenza Vaccine
25%
Coronavirinae
25%
Diseases
25%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
TNF Inhibitor
100%
Hepatitis Delta Virus
100%
Neutralizing Antibody
50%
Inflammatory Disorder
50%
Immunosuppression
25%
Monoclonal Antibody
25%
Antibody Response
25%
Titer
25%
Immunosuppressive Drug
25%
Antibody Titer
25%
Influenza
25%
Susceptible Population
25%
COVID-19
25%
Influenza Vaccine
25%
Virus
25%